Literature DB >> 15215093

Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.

Christopher Cianci1, Eugene V Genovesi, Lucinda Lamb, Ivette Medina, Zheng Yang, Lisa Zadjura, Hyekyung Yang, Celia D'Arienzo, Ny Sin, Kuo-Long Yu, Keith Combrink, Zhufang Li, Richard Colonno, Nicholas Meanwell, Junius Clark, Mark Krystal.   

Abstract

BMS-433771 is a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro. Mechanism of action studies have demonstrated that BMS-433771 halts virus entry through inhibition of F protein-mediated membrane fusion. BMS-433771 also exhibited in vivo efficacy following oral administration in a mouse model of RSV infection (C. Cianci, K. Y. Yu, K. Combrink, N. Sin, B. Pearce, A. Wang, R. Civiello, S. Voss, G. Luo, K. Kadow, E. Genovesi, B. Venables, H. Gulgeze, A. Trehan, J. James, L. Lamb, I. Medina, J. Roach, Z. Yang, L. Zadjura, R. Colonno, J. Clark, N. Meanwell, and M. Krystal, Antimicrob. Agents Chemother. 48:413-422, 2004). In this report, the in vivo efficacy of BMS-433771 against RSV was further examined in the BALB/c mouse and cotton rat host models of infection. By using the Long strain of RSV, prophylactic efficacy via oral dosing was observed in both animal models. A single oral dose, administered 1 h prior to intranasal RSV inoculation, was as effective against infection as a 4-day b.i.d. dosing regimen in which the first oral dose was given 1 h prior to virus inoculation. Results of dose titration experiments suggested that RSV infection was more sensitive to inhibition by BMS-433771 treatment in the BALB/c mouse host than in the cotton rat. This was reflected by the pharmacokinetic and pharmacodynamic analysis of the efficacy data, where the area under the concentration-time curve required to achieve 50% of the maximum response was approximately 7.5-fold less for mice than for cotton rats. Inhibition of RSV by BMS-433771 in the mouse is the result of F1-mediated inhibition, as shown by the fact that a virus selected for resistance to BMS-433771 in vitro and containing a single amino acid change in the F1 region was also refractory to treatment in the mouse host. BMS-433771 efficacy against RSV infection was also demonstrated for mice that were chemically immunosuppressed by cyclophosphamide treatment, indicating that compound inhibition of the virus did not require an active host immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215093      PMCID: PMC434195          DOI: 10.1128/AAC.48.7.2448-2454.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  VP-14637 ViroPharma.

Authors:  J McKimm-Breschkin
Journal:  Curr Opin Investig Drugs       Date:  2000-12

2.  Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection.

Authors:  J J Anderson; J Norden; D Saunders; G L Toms; R Scott
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

3.  Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections.

Authors:  P R Wyde; D K Moore-Poveda; E De Clercq; J Neyts; A Matsuda; N Minakawa; E Guzman; B E Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane.

Authors:  R R Tidwell; J D Geratz; W A Clyde; K U Rosenthal; E J Dubovi
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  RFI-641, a potent respiratory syncytial virus inhibitor.

Authors:  Clayton C Huntley; William J Weiss; Anna Gazumyan; Aron Buklan; Boris Feld; William Hu; Thomas R Jones; Timothy Murphy; Antonia A Nikitenko; Bryan O'Hara; Gregory Prince; Susan Quartuccio; Yuri E Raifeld; Philip Wyde; John F O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Prevalence of ovine and bovine respiratory syncytial virus infections in cattle determined with a synthetic peptide-based immunoassay.

Authors:  S T Grubbs; S A Kania; L N Potgieter
Journal:  J Vet Diagn Invest       Date:  2001-03       Impact factor: 1.279

8.  In vivo inhibition of respiratory syncytial virus by ribavirin.

Authors:  J F Hruska; P E Morrow; S C Suffin; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

9.  Alteration of pulmonary macrophage function by respiratory syncytial virus infection in vitro.

Authors:  G Franke-Ullmann; C Pförtner; P Walter; C Steinmüller; M L Lohmann-Matthes; L Kobzik; J Freihorst
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

10.  Respiratory syncytial virus infection in anti-mu-treated mice.

Authors:  B S Graham; L A Bunton; J Rowland; P F Wright; D T Karzon
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more
  24 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion.

Authors:  Christopher Cianci; David R Langley; Douglas D Dischino; Yaxiong Sun; Kuo-Long Yu; Anne Stanley; Julia Roach; Zhufang Li; Richard Dalterio; Richard Colonno; Nicholas A Meanwell; Mark Krystal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-06       Impact factor: 11.205

3.  Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV).

Authors:  Aurelio Bonavia; Michael Franti; Erin Pusateri Keaney; Kelli Kuhen; Mohindra Seepersaud; Branko Radetich; Jian Shao; Ayako Honda; Janetta Dewhurst; Kara Balabanis; James Monroe; Karen Wolff; Colin Osborne; Leanne Lanieri; Keith Hoffmaster; Jakal Amin; Judit Markovits; Michelle Broome; Elizabeth Skuba; Ivan Cornella-Taracido; Gerard Joberty; Tewis Bouwmeester; Lawrence Hamann; John A Tallarico; Ruben Tommasi; Teresa Compton; Simon M Bushell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

4.  Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.

Authors:  Song Feng; Di Hong; Baoxia Wang; Xiufang Zheng; Kun Miao; Lisha Wang; Hongying Yun; Lu Gao; Shuhai Zhao; Hong C Shen
Journal:  ACS Med Chem Lett       Date:  2015-01-25       Impact factor: 4.345

5.  Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection.

Authors:  Robert Jordan; Matt Shao; Richard L Mackman; Michel Perron; Tomas Cihlar; Sandy A Lewis; Eugene J Eisenberg; Anne Carey; Robert G Strickley; Jason W Chien; Mark L Anderson; Heather A McEligot; Nicole E Behrens; Laurel J Gershwin
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

Review 6.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

7.  Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice.

Authors:  Laura E Luque; Olga A Bridges; John N Mason; Kelli L Boyd; Allen Portner; Charles J Russell
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide.

Authors:  Michael N Ha; Sébastien Delpeut; Ryan S Noyce; Gary Sisson; Karen M Black; Liang-Tzung Lin; Darius Bilimoria; Richard K Plemper; Gilbert G Privé; Christopher D Richardson
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

9.  Structure-guided design of small-molecule therapeutics against RSV disease.

Authors:  Robert Cox; Richard K Plemper
Journal:  Expert Opin Drug Discov       Date:  2016-04-21       Impact factor: 6.098

Review 10.  The infectious march: the complex interaction between microbes and the immune system in asthma.

Authors:  Terianne Wong; Gary Hellermann; Shyam Mohapatra
Journal:  Immunol Allergy Clin North Am       Date:  2010-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.